T1	intervention 26 35	tamoxifen
T2	condition 552 580	coronary heart disease (CHD)
T3	No-of-participants 899 905	13 388
T4	eligibility 906 947	women at increased risk for breast cancer
T5	control 1026 1033	placebo
T6	No-of-participants 1078 1084	13 194
T7	outcome-Measure 1129 1169	Fatal and nonfatal myocardial infarction
T8	outcome-Measure 1171 1186	unstable angina
T9	outcome-Measure 1192 1205	severe angina
T10	outcome 1288 1351	Cardiovascular event rates were not statistically significantly
T11	intervention-participants 1503 1507	6074
T12	control-participants 1528 1532	6072
T13	outcome 1640 1668	fatal myocardial infarction,
T14	outcome 1693 1723	nonfatal myocardial infarction
T15	outcome 1749 1764	unstable angina
T16	outcome 1794 1807	severe angina
T17	intervention-participants 1828 1831	516
T18	control-participants 1852 1855	532
T19	outcome 1937 1964	fatal myocardial infarction
T20	outcome 1990 2020	nonfatal myocardial infarction
T21	outcome 2046 2061	unstable angina
T22	outcome 2091 2104	severe angina
